ANKE BIO(300009) 华鑫证券·2024-04-08 16:00Investment Rating - The investment rating for the company is "Buy (Maintain)" [7] Core Views - The company has shown strong growth in its main product, growth hormone, with a sales revenue increase of 36.24% in 2023, contributing significantly to the overall performance [7][8] - The approval of Trastuzumab injection is expected to provide additional revenue for the company, with plans for full-scale production in 2024 [7][8] - The company is actively increasing its R&D efforts, with a 53.41% year-on-year increase in R&D expenses in 2023, focusing on both biopharmaceuticals and targeted cancer drugs [7][8] Financial Forecast - Main revenue (in million yuan) is projected to grow from 2,866 in 2023 to 3,583 in 2024, 4,378 in 2025, and 5,296 in 2026, with growth rates of 22.9%, 25.0%, 22.2%, and 21.0% respectively [3][11] - Net profit attributable to shareholders (in million yuan) is expected to rise from 847 in 2023 to 1,080 in 2024, 1,360 in 2025, and 1,685 in 2026, with growth rates of 20.5%, 27.5%, 25.9%, and 23.9% respectively [3][11] - The diluted earnings per share (in yuan) are forecasted to increase from 0.51 in 2023 to 0.64 in 2024, 0.81 in 2025, and 1.01 in 2026 [3][11] - The return on equity (ROE) is projected to improve from 21.5% in 2023 to 24.0% in 2024, 26.1% in 2025, and 27.6% in 2026 [3][11]